Safety & Side Effects

What we know about DSIP safety, and the bigger gray-market risk

Historical DSIP studies reported it as generally well tolerated, with few major adverse events. But that reassurance is thin: the studies were small, old, and short, so the real risk for most people is not the peptide’s known pharmacology but the unregulated product it comes in.

This unit separates the modest reassurance from the genuine open questions, covers the sterility and purity risks of gray-market vials, and ends on an honest bottom line.